Ascendis Pharma Priced, Nasdaq: ASND

Developing long-acting treatments for growth hormone deficiency.

Industry: Health Care

Latest Trade: $28.05 0.00 (0.0%)

First Day Return: +4.6%

Return from IPO: +55.8%

Industry: Health Care

We are a clinical stage biopharmaceutical company applying our TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs. We are developing our lead product candidate, TransCon human growth hormone, for once-weekly administration to treat growth hormone deficiency, and other indications. We have successfully completed a Phase 2 study of TransCon hGH in adults with GHD and have fully enrolled our ongoing six-month Phase 2 study in children with GHD. In December 2014, we reported positive interim six-month height velocity data from 25 patients, representing approximately 50% of the total enrollment in the study, completing all six months of treatment, and we expect to report topline data for all patients in this study in mid-2015. Using our TransCon technology, we have established a new paradigm that combines the benefits of conventional prodrug and sustained release technologies, and is broadly applicable to proteins, peptides and small molecules. In addition to TransCon hGH, we have developed a pipeline of long-acting prodrug product candidates such as TransCon Treprostinil, currently in a Phase 1 clinical proof-of-concept study, for the treatment of pulmonary arterial hypertension, TransCon Insulin, for the treatment of diabetes, partnered with Sanofi, and TransCon Ranibizumab, in the field of ophthalmology, partnered with Genentech.
more less
IPO News for Ascendis Pharma
more
IPO Data
IPO File Date 12/18/2014
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.0
Deal Size ($mm) $108
IPO Data
IPO Date 01/27/2015
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.0
Deal Size ($mm) $108
Underwriters
more
Company Data
Headquarters Hellerup, Denmark
Founded 2006
Employees 55
Website www.ascendispharma.com